Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
- PMID: 36160241
- PMCID: PMC9493352
- DOI: 10.3389/fmicb.2022.988728
Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
Abstract
Antimicrobial resistance has become one of the greatest threats to human health, and new antibacterial treatments are urgently needed. As a tool to develop novel therapies, animal models are essential to bridge the gap between preclinical and clinical research. However, despite common usage of in vivo models that mimic clinical infection, translational challenges remain high. Standardization of in vivo models is deemed necessary to improve the robustness and reproducibility of preclinical studies and thus translational research. The European Innovative Medicines Initiative (IMI)-funded "Collaboration for prevention and treatment of MDR bacterial infections" (COMBINE) consortium, aims to develop a standardized, quality-controlled murine pneumonia model for preclinical efficacy testing of novel anti-infective candidates and to improve tools for the translation of preclinical data to the clinic. In this review of murine pneumonia model data published in the last 10 years, we present our findings of considerable variability in the protocols employed for testing the efficacy of antimicrobial compounds using this in vivo model. Based on specific inclusion criteria, fifty-three studies focusing on antimicrobial assessment against Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii were reviewed in detail. The data revealed marked differences in the experimental design of the murine pneumonia models employed in the literature. Notably, several differences were observed in variables that are expected to impact the obtained results, such as the immune status of the animals, the age, infection route and sample processing, highlighting the necessity of a standardized model.
Keywords: Gram-negative; PK/PD; antimicrobial; antimicrobial efficacy studies; lung infection; murine pneumonia model.
Copyright © 2022 Arrazuria, Kerscher, Huber, Hoover, Lundberg, Hansen, Sordello, Renard, Aranzana-Climent, Hughes, Gribbon, Friberg and Bekeredjian-Ding.
Conflict of interest statement
JLH was employed by GlaxoSmithKline Pharmaceuticals. SS and SR were employed by Evotec. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections.Front Microbiol. 2022 Sep 8;13:988725. doi: 10.3389/fmicb.2022.988725. eCollection 2022. Front Microbiol. 2022. PMID: 36160186 Free PMC article.
-
Degradable antimicrobial polycarbonates with unexpected activity and selectivity for treating multidrug-resistant Klebsiella pneumoniae lung infection in mice.Acta Biomater. 2019 Aug;94:268-280. doi: 10.1016/j.actbio.2019.05.057. Epub 2019 May 24. Acta Biomater. 2019. PMID: 31129359
-
Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.Clin Microbiol Infect. 2022 Oct;28(10):1367-1374. doi: 10.1016/j.cmi.2022.05.003. Epub 2022 May 20. Clin Microbiol Infect. 2022. PMID: 35598857
-
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.Int J Antimicrob Agents. 2021 Jun;57(6):106328. doi: 10.1016/j.ijantimicag.2021.106328. Epub 2021 Mar 27. Int J Antimicrob Agents. 2021. PMID: 33785362
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
Cited by
-
Aerosolized delivery of ESKAPE pathogens for murine pneumonia models.Sci Rep. 2024 Jan 31;14(1):2558. doi: 10.1038/s41598-024-52958-9. Sci Rep. 2024. PMID: 38297183 Free PMC article.
-
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.J Antimicrob Chemother. 2025 Jun 3;80(6):1552-1559. doi: 10.1093/jac/dkaf100. J Antimicrob Chemother. 2025. PMID: 40152266 Free PMC article.
-
All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches.Antibiotics (Basel). 2023 Apr 1;12(4):690. doi: 10.3390/antibiotics12040690. Antibiotics (Basel). 2023. PMID: 37107052 Free PMC article. Review.
-
Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models of Escherichia coli and Acinetobacter baumannii.Antibiotics (Basel). 2024 Apr 24;13(5):386. doi: 10.3390/antibiotics13050386. Antibiotics (Basel). 2024. PMID: 38786115 Free PMC article.
-
Galleria mellonella (Greater Wax Moth) as a Reliable Animal Model to Study the Efficacy of Nanomaterials in Fighting Pathogens.Nanomaterials (Basel). 2025 Jan 3;15(1):67. doi: 10.3390/nano15010067. Nanomaterials (Basel). 2025. PMID: 39791825 Free PMC article. Review.
References
-
- Avery L. M., Abdelraouf K., Nicolau D. P. (2018). Assessment of the in vivo efficacy of WCK 5222 (Cefepime-Zidebactam) against carbapenem-resistant Acinetobacter baumannii in the neutropenic murine lung infection model. Antimicrob. Agents Chemother. 62:e00948-18. 10.1128/AAC.00948-18 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous